Advancing Cancer Treatment Through Research & Innovation
Our research focuses on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Current Research Projects
Our current research projects are focused on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Efficacy of Compression Therapy for Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Early Breast Cancer: Insights from a Single-Centre Experience in Bangladesh
Prospective
Research Objectives:
- • Incidence of CTCAE version 5 grade 2 or higher CIPN in both upper and lower extremities during entire period of chemotherapy.
The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial
Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months
Research Objectives:
- • A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.
Recent Publications
Peer-reviewed research contributions published in leading oncology journals, advancing the field of cancer treatment.
Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population
This Randomized Clinical Trial (RCT) was carried out in the Department of Medical Oncology at National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka. Patients were enrolled from January …
Key Findings:
Significant G-1/2 Hb% was found in Day7 in TP (16.67%) and EP (10.52%) arm and in 6 months EP (31.58%) and TP (29.17%). WBC G-1/2 …
Primary Jejunal Gastrointestinal Stromal Tumor: Diagnosis Delay of 3 Years but Successful Management in Early Stage (II) by Surgery and Adjuvant Therapy
In the digestive system, mesenchymal origin of tumors is quite rare; in general, they are recognized as gastrointestinal stromal tumors (GISTs). The incidence of GISTs is very low (2 in …
Key Findings:
We present the case of a 62-year-old Bangladeshi female with a history of GI bleeding 3 years earlier; the cause of the bleeding had not …
Sister Mary Jospeh's nodule as initial presentation of carcinoma caecum-case report and literature review
Umbilical metastases [Sister Mary Joseph's nodules (SMJN)] are relatively rare and are associated usually with advanced intra-abdominal tumors from the gastrointestinal tract (GIT) or from the gynecological malignancies and they …
Key Findings:
Umbilical metastases [Sister Mary Joseph's nodules (SMJN)] are relatively rare and are associated usually with advanced intra-abdominal tumors from the gastrointestinal tract (GIT) or from …
Showing 16 to 18 of 19 publications
Conference Presentations & Speaking Engagements
Sharing research findings and clinical insights at leading medical conferences worldwide.
15TH EUROPEAN BREAST CANCER CONFERENCE
The Impact of Dual vs Single Anti-HER2: A Real-World Retrospective Analysis of Treatment Outcome in Bangladesh
Background The integration of dual HER2 blockade (trastuzumab + pertuzumab, PH) has improved outcomes in HER2-positive breast cancer, particularly in neoadjuvant and metastatic settings. However, evidence from routine clinical practice in low- and middle-income countries is limited. This study aimed to evaluate real-world survival outcomes, response rates, and safety of dual versus single blockade (trastuzumab alone, H) across treatment settings.
ISRS 2026
FRACTIONATED STEREOTACTIC RADIOTHERAPY (FSRT) FOR OLIGOMETASTATIC DISEASE: A SINGLE-CENTER EXPERIENCE FROM BANGLADESH
Background: Oligometastatic disease represents a biologically intermediate state where aggressive metastasis-directed therapy may improve durable disease control. Fractionated stereotactic radiotherapy (FSRT)enables safe delivery of ablative doses to intracranial and extracranial lesions. We report updatedoutcomes of linac-based FSRT with the inclusion of an additional patient.
40th The Society for Immunotherapy of Cancer (SITC) 2025
The Role of Concomitent MET Amplification and High PD-L1 Expression in Non-Small Cell Lung Cancer: A case report of Implications for Targeted Therapy and Immunotherapy
MET amplification occurs in approximately 1-5% of treatment-naïve non- small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase inhibitors (TKIs), where it's observed in about 15% of cases. This case underscores the coexistence of MET gene amplification and high PD-L1 expression in NSCLC, which has significant therapeutic implications. The presence of MET amplification suggests potential benefit from MET- targeted therapies, while high PD-L1 expression indicates responsiveness to immune checkpoint inhibitors. When MET amplification and high PD-L1 co-exist, the optimal treatment strategy can be challenging. The integration of molecular and immunohistochemical data guides personalized treatment strategies for this patient.
40th The Society for Immunotherapy of Cancer (SITC) 2025
Pathological complete response with Pembrolizumab in combination with chemotherapy for Neoadjuvant Treatment of Early Triple Negative Breast Cancer: A Single-center prospective study from Bangladesh.
Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen- receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT)settings.
Showing 1 to 4 of 8 presentations